Journal
CANCER LETTERS
Volume 579, Issue -, Pages -Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2023.216456
Keywords
Oncolytic adenovirus; Pancreatic cancer; Cancer specificity; Therapeutic efficacy
Categories
Ask authors/readers for more resources
This review summarizes the development of oncolytic adenovirus as a novel therapeutic approach for pancreatic cancer, aiming to overcome the challenges posed by the tumor microenvironment.
Pancreatic cancer remains one of the deadliest cancers with extremely high mortality rate, and the number of cases is expected to steadily increase with time. Pancreatic cancer is refractory to conventional cancer treatment options, like chemotherapy and radiotherapy, and commercialized immunotherapeutics, owing to its immunosuppressive and desmoplastic phenotype. Due to these reasons, development of an innovative treatment option that can overcome these challenges posed by the pancreatic tumor microenvironment (TME) is in an urgent need. The present review aims to summarize the evolution of oncolytic adenovirus (oAd) engineering and usage as therapeutics (either monotherapy or combination therapy) over the last decade to overcome these hurdles to instigate a potent antitumor effect against desmoplastic and immunosuppressive pancreatic cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available